Medtronic Cardiovascular
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Medtronic Cardiovascular sits in the top decile of US sponsors by registered trial count (#407 of 15,742 sponsors by registered trial count).
Medtronic Cardiovascular: 44 sponsored US clinical trials, 4 recruiting.
Medtronic Cardiovascular sponsors 44 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 23 completed. 2 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Severe Aortic Stenosis, with 2 trials.
Top-decile sponsor footprint
Medtronic Cardiovascular ranks in the top decile of sponsors by registered trial count (#407 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
23 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (74.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
44 total, page 1 of 1
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347
TTVR Early Feasibility Study
NCT04433065
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
NCT03242642
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Harmony TPV Post-Approval Study
NCT05077774
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
NCT04722250
Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study
NCT03635424
Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients
NCT02701283
Transcatheter Mitral Valve Replacement System (TMVR) Pilot Study and The Early Feasibility Study of the TMVR Transseptal System
NCT02322840
Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement
NCT01675440
ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)
NCT01534819
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
NCT01586910
Medtronic Evolut™ EXPAND TAVR I Feasibility Study
NCT04639258
DISSECT-N Post Market Data Collection Registry
NCT04267055
Optimize PRO Study
NCT04091048
Medtronic CoreValve Evolut R U.S. Clinical Study (Evolut 34R Addendum)
NCT02746809
The Medtronic TAVR 2.0 US Clinical Study
NCT02738853
Valiant Evo US Clinical Trial
NCT02652949
Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Descending TAA and Chronic Dissections
NCT02365467
Endurant Evo US Clinical Trial
NCT02393716
Medtronic CoreValve Evolut R U.S. Clinical Study
NCT02207569
Safety and Efficacy of Valiant Mona LSA Stent Graft System
NCT01839695
Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial
NCT01585779
Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement
NCT01531374
Endurant Stent Graft System Post Approval Study (ENGAGE PAS)
NCT01379222
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement
NCT01240902
Melody® Transcatheter Pulmonary Valve Post-Approval Study
NCT01186692
Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections
NCT01114724
Study to Determine if the Valiant Stent Graft is Safe and Effective in Treating Patients Who Have a Blunt Thoracic Aortic Injury
NCT01092767
Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery
NCT01334866
ATS 3f(r) Aortic Bioprosthesis Model 1000 Post Approval Study
NCT01116037
Post-Approval Clinical Study of the Talent Thoracic Stent Graft to Treat Thoracic Aortic Aneurysms (THRIVE)
NCT00805948
Evaluation of the Cardioblate Closure Device in Facilitating Occlusion of the Left Atrial Appendage
NCT00841529
Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms
NCT00816062
Endurant Bifurcated and Aorto-Uni-Iliac (AUI) Stent Graft System
NCT00705718
The Pivotal Study of the Aptus Endovascular AAA Repair System
NCT00507559
Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study
NCT00431834
Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Investigational Device Exemption Cohort
NCT00740870
Valor II: The Valiant Thoracic Stent Graft System Clinical Study
NCT00413231
The (PIVOTAL) Study
NCT00444821
VALOR: The Talent Thoracic Stent Graft System Clinical Study
NCT00604799
AneuRx Post Market Study in the Treatment of AAA
NCT00604552
ATS 3f(r) Aortic Bioprosthesis Model 1000, 19mm
NCT00657826
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
What is open in the Medtronic Cardiovascular pipeline
4 recruiting of 44 indexed (9% open); 23 completed (52%).
Phase mix: 2 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Severe Aortic Stenosis (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Medtronic Cardiovascular: open-pipeline peers nationwide
Peers matched on 44 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Medtronic Cardiovascular sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 44 trials (± recruiting share)
- Agios Pharmaceuticals · 44 trials · 7% recruiting
- Beth Israel Medical Center · 44 trials · 0% recruiting
- Innovative Medical · 44 trials · 0% recruiting
- Kowa Research Institute · 44 trials · 0% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Alkermes · 9% recruiting · 66 trials
- DBV Technologies · 9% recruiting · 11 trials
- Florida Gulf Coast University · 9% recruiting · 11 trials
- Genfit · 9% recruiting · 11 trials
Related
What to do with this Medtronic Cardiovascular page
44 registered trials is a research-attention snapshot, not an endorsement of Medtronic Cardiovascular or any single study.
- 4 of Medtronic Cardiovascular's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Severe Aortic Stenosis is the condition Medtronic Cardiovascular studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Severe Aortic Stenosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Medtronic Cardiovascular pipeline card: 44 registered trials from official public datasets.Report a data error.